Leading in Cell and Gene Therapy CDMO
Service
Excellence
Leading in Cell and Gene Therapy CDMO
Innovative
Solutions
scroll down
ENCELL Co. Ltd. offers
contract development and manufacturing (CDMO) services
and contract quality testing (CQT) services
through the operation of globally recognized GMP facilities.
CDMO
The ROCKET Platform represents a multi-product
GMP production technology-based CDMO service.
Through the operation of globally recognized GMP facilities,
ENCELL has enhanced its quality management and capabilities,
thereby establishing the capacity to secure contracts for global products.
CQT Services
Raw materials during the manufacturing process:
IPC, DS/DP, stability testing
At ENCELL Co., Ltd., we conduct comprehensive quality and
characterization testing for all samples generated during
the production process, including raw materials, IPC, and DS/DP.
This allows us to guarantee the highest quality standards for our products.
Our mission is to elevate
the quality of advanced biopharmaceuticals through
the application of cutting-edge technology and expertise.
Research Center
CDMO and Contract Quality Services for Cell and Gene Therapies
Our research center is a leading provider of contract research
and quality assurance services for cell and gene therapies.
We specialize in GMP production processes and quality analysis development,
as well as cell characterization and mechanism studies.
Platform Technology
Our platform technology leverages next-generation
stem cell technology to achieve high yields and efficacy.
ENCELL's innovative platform technology addresses key challenges
in cell aging, efficacy, and high-yield production,
offering a cost-effective solution to enhance productivity and profitability.
Pipeline
The Pipeline Overview demonstrates
ENCELL's technological capabilities.
Our company is committed to developing cutting-edge therapeutic products,
including next-generation stem cell therapies, cancer immunotherapy cell treatments,
and AAV-based gene therapies.
Company Information
Notice of Privacy Policy Amendment and New CCTV Policy (Effective November 2, 2026)
.ecpp-nte{color:#202733;font-family:"Pretendard","Noto Sans KR","Malgun Gothic","맑은 고딕",Arial,sans-serif;font-size:19px;line-height:1.75;word-break:keep-all;overflow-wrap:break-word;max-width:1120px;margin:0 auto;padding:24px 0 48px;text-align:left;} .ecpp-nte,.ecpp-nte *{box-sizing:border-box;} .ecpp-nte p{margin:0 0 10px;} .ecpp-nte .nt-intro{padding:22px 26px;background:#fff;border:1px solid #dfe7f1;border-left:5px solid #0b4f9c;border-radius:12px;margin-bottom:22px;} .ecpp-nte .nt-date{display:inline-block;margin:6px 0 0;padding:6px 14px;background:#eef5fc;border:1px solid #cfe0f2;border-radius:999px;color:#12365f;font-weight:700;font-size:16px;} .ecpp-nte .nt-h{display:flex;align-items:center;gap:10px;margin:30px 0 12px;font-size:22px;font-weight:800;color:#12365f;line-height:1.4;} .ecpp-nte .nt-no{display:inline-flex;align-items:center;justify-content:center;width:28px;height:28px;border-radius:8px;background:#0b4f9c;color:#fff;font-size:14px;font-weight:800;flex:0 0 auto;} .ecpp-nte .nt-wrap{width:100%;overflow-x:auto;border:1px solid #dce5ef;border-radius:12px;} .ecpp-nte table{width:100% !important;min-width:720px;border-collapse:separate;border-spacing:0;background:#fff;margin:0;table-layout:fixed !important;} .ecpp-nte col.c1{width:20% !important;}.ecpp-nte col.c2{width:33% !important;}.ecpp-nte col.c3{width:47% !important;} .ecpp-nte .nt-wrap table tr>*:nth-child(1){width:20% !important;}.ecpp-nte .nt-wrap table tr>*:nth-child(2){width:33% !important;}.ecpp-nte .nt-wrap table tr>*:nth-child(3){width:47% !important;} .ecpp-nte th,.ecpp-nte td{padding:12px 14px;border-right:1px solid #e4eaf1;border-bottom:1px solid #e4eaf1;vertical-align:middle;line-height:1.6;font-size:18px;text-align:left;word-break:normal;} .ecpp-nte tr>*:last-child{border-right:0;} .ecpp-nte tr:last-child>*{border-bottom:0;} .ecpp-nte thead th{background:#eef5fc;color:#12365f;font-weight:800;text-align:center;} .ecpp-nte tbody th{background:#f7faff;color:#12365f;font-weight:700;} .ecpp-nte td.old{color:#667085;} .ecpp-nte .tag{display:inline-block;margin-left:4px;padding:0 7px;border-radius:6px;background:#0b4f9c;color:#fff;font-size:13px;font-weight:700;line-height:1.7;vertical-align:1px;} .ecpp-nte .nt-box{padding:18px 22px;background:#fff;border:1px solid #dfe7f1;border-radius:12px;} .ecpp-nte .nt-contact{margin-top:26px;padding:16px 20px;background:#f7faff;border-radius:10px;color:#344054;} .ecpp-nte .nt-contact b{color:#12365f;} .ecpp-nte .lang-note{margin-top:18px;padding:12px 18px;border:1px dashed #cfe0f2;border-radius:10px;color:#475467;font-size:15px;} @media (max-width:760px){.ecpp-nte{font-size:16px;padding:12px 0 32px;}.ecpp-nte .nt-intro,.ecpp-nte .nt-box{padding:16px 16px;}.ecpp-nte .nt-h{font-size:20px;}.ecpp-nte table{min-width:560px;}.ecpp-nte th,.ecpp-nte td{padding:10px 11px;font-size:15px;}} Hello, this is ENCell Co., Ltd.To reflect its current personal information processing practices and relevant laws, the Company has fully amended its Privacy Policy and newly established a Fixed Visual Data Processing Device Operation and Management Policy. Please refer to the key changes below.Effective date: Monday, November 2, 2026 1Key changes to the Privacy Policy CategoryBeforeAfter(effective Nov 2, 2026) NamePersonal Information Handling PolicyPrivacy Policy (name aligned with the Personal Information Protection Act) Items processed and retention periodCustomer service: name, contact number, email address (1 year)Job applications: academic background, career and other résumé details (180 days after employment status is confirmed)Customer inquiries: name, contact number, email, inquiry details, [Optional] information in attached files (1 year from collection)Job applicants: information in the résumé (destroyed without delay after the recruitment process ends)External visitors: name, date and time of visit, purpose of visit, affiliation, contact number, signature (5 years from collection) New Legal basisConsent of the data subject; Fair Hiring Procedure ActLegal basis specified for each item Unique identification and sensitive information; childrenOnly provisions on the exercise of rights by legal representatives of children under 14States that unique identification information, sensitive information, and personal information of children under 14 are not collected Provision to third partiesNot provided in principle, with exceptions stated separatelyProvided only with the consent of the data subject or where permitted by law; currently not provided EntrustmentNo entrustmentDiscloses entrustment of website development and maintenance and server hosting (WEBMOA Corp.) DestructionStored in a separate database, etc. after the purpose is achieved, then destroyedDestroyed without delay after confirmation by the responsible department; information required to be retained by law is stored separately Rights of data subjectsRequests to view, correct, or deleteGuidance on requests for access, correction or deletion, suspension of processing, withdrawal of consent, exercise through representatives, and objections Security measuresPassword encryption, measures against hacking, etc.Reorganized into managerial, technical, and physical measures CookiesNot usedUsed for website session maintenance and security; how to refuse is provided Automated decisions-States that no automated decisions are made New Chief Privacy OfficerPersonal Information Manager (Tel. +82-2-6205-8050)Chief Privacy Officer: Head of Management Planning DivisionResponsible department: Management Planning Division (Tel. +82-2-6205-8058) Remedies for infringement-Guidance on four organizations, including the Personal Information Dispute Mediation Committee New Changes to the policyNotice 7 days before changesDisclosure of changes and the effective date, comparison before and after changes, and access to previous versions 2Establishment of the Fixed Visual Data Processing Device Operation and Management Policy The Company has newly established a policy that describes the purposes of installation, installation locations, recording range, retention period, and managers of the fixed visual data processing devices (CCTV) installed and operated at its business sites. 3How to view The amended Privacy Policy and the Fixed Visual Data Processing Device Operation and Management Policy are available on the website. The previous privacy policy can be found under "Privacy Policy versions" in the Privacy Policy.View the previous privacy policy → Contact Management Planning Division (Tel. +82-2-6205-8058 / Email encell@encellinc.com) Thank you. This English notice is provided for reference only. In the event of any discrepancy between the Korean and English versions, the Korean version shall prevail.
Cell Therapies and ENCell Forge Strategic APAC Partnership to Advance Cell and Gene Therapy Manufacturing
Melbourne, Australia & Seoul, Republic of Korea — November 05, 2025 — Cell Therapies Pty Ltd (“Cell Therapies”), Australia’s leading cell and gene therapy (CGT) CDMO, and ENCell Co., Ltd. (“ENCell”), a Korea-based advanced biopharmaceutical CDMO, today announced the signing of a Memorandum of Understanding (MOU) aimed at expanding access to CGT development and manufacturing across the Asia-Pacific (APAC) region. The partnership brings together the companies’ world-class GMP manufacturing facilities, technical and regulatory expertise, and extensive regional networks to accelerate the development and delivery of next-generation cell and gene therapies for patients across Asia-Pacific. Strategic Focus Areas Under the MOU, the companies will collaborate across four core areas that are critical to strengthening APAC’s CGT ecosystem: 1. Enhancing CGT Manufacturing and Process Development Cell Therapies and ENCell will jointly optimize and scale manufacturing processes for a broad portfolio of advanced therapies, including MSC, CAR-T, CAR-NK, and iPSC-derived cell therapies. Collaboration includes shared use of GMP-certified facilities for global clinical and commercial supply and co-development of next-generation iPSC-based manufacturing platforms and decentralized production models. 2. Regulatory Alignment and Quality Harmonization The partners will align regulatory strategies across Korea, Australia, Japan, and broader APAC jurisdictions. This includes co-preparation of manufacturing-related regulatory documents and sharing technical and quality expertise to support efficient regional and global submissions. 3. Joint Market Engagement and APAC Expansion The companies plan to conduct joint business development activities targeting regional biotech and pharmaceutical firms, deepen partnerships with hospitals and research institutions, and build a trusted multi-site CGT manufacturing network capable of supporting global clients. 4. Workforce Development and Research Innovation To support the rapid growth of CGT in APAC, Cell Therapies and ENCell will co-develop training programs to strengthen the talent pipeline and jointly pursue research initiatives in next-generation technologies such as allogeneic therapies, iPSC platforms, high-efficiency manufacturing systems, and sustainability-oriented production strategies. The collaboration will also explore cost-of-goods (COGS) optimization to improve long-term manufacturing efficiency. Statements from Company Leaders Dr. Bev Menner, CEO of Cell Therapies, emphasized the importance of the partnership:“This collaboration represents a significant step toward enhancing patient access to innovative cell and gene therapies across the Asia-Pacific region. By working closely with ENCell, we aim to strengthen technical exchange, enhance manufacturing capacity, and establish a robust supply network to support the next generation of advanced therapies.” Dr. Jong Wook Chang, CEO of ENCell, expressed confidence in the partnership’s value:“ENCell fully supports Cell Therapies’ vision to expand the CGT ecosystem throughout the APAC region. By combining the expertise and manufacturing capabilities of both companies, we expect to establish a high-quality CGT production platform connecting Korea and Australia. ENCell will continue to collaborate with global partners to deliver optimal CDMO services that support successful clinical trials and commercialization for our clients.” Advancing APAC’s CGT Ecosystem This MOU is recognized as a model of meaningful cross-border collaboration, supporting the rapid expansion of the CGT industry in the APAC region. By leveraging each country's strengths and shared scientific capabilities, Cell Therapies and ENCell aim to enable regional biotech and pharmaceutical companies to advance their clinical and commercial pipelines with enhanced speed and reliability through a trusted CGT CDMO network. The companies intend to progress to a definitive agreement within the next two to three months and will immediately begin identifying joint project opportunities and executing technical collaboration initiatives.
.jpg)
ENCell Co., Ltd. Selected for the 2020 Seoul Business Agency Bio-Medical Technology Commercialization Support Program
ENCell Co., Ltd. has been selected as a final participant in the 2020 Seoul Business Agency Bio-Medical Technology Commercialization Support Program. The selected project is titled "Development of a Treatment for Duchenne Muscular Dystrophy Utilizing High-Potency/High-Efficiency GMP Technology for Large-Scale Expansion of Early-Passage Umbilical Cord-Derived Mesenchymal Stem Cells." ENCell Co., Ltd. will serve as the lead organization (Project Manager: CEO Jongwook Jang), with Samsung Medical Center participating as a collaborating institution (Division Manager: Professor Jihoon Lee, Department of Pediatrics).Through this project, ENCell aims to accelerate clinical trials and commercialization of its stem cell-based treatment for Duchenne Muscular Dystrophy. By securing funding support from Seoul City, the company is committed to contributing to the growth of Seoul’s bio-medical industry and pledges to dedicate itself to the development of therapies for the rare disease Duchenne Muscular Dystrophy.